Raymond James Trust’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $6.09M | Buy |
117,655
+5,932
| +5% | +$278K | 0.13% | 147 |
|
|
2024
Q2 | $4.64M | Buy |
111,723
+3,500
| +3% | +$157K | 0.11% | 172 |
|
|
2024
Q1 | $5.87M | Buy |
108,223
+2,980
| +3% | +$152K | 0.14% | 144 |
|
|
2023
Q4 | $5.4M | Sell |
105,243
-21,856
| -17% | -$1.15M | 0.14% | 146 |
|
|
2023
Q3 | $7.38M | Sell |
127,099
-2,736
| -2% | -$168K | 0.22% | 100 |
|
|
2023
Q2 | $8.3M | Buy |
129,835
+1,611
| +1% | +$108K | 0.24% | 96 |
|
|
2023
Q1 | $8.89M | Sell |
128,224
-1,036
| -0.8% | -$73.1K | 0.28% | 80 |
|
|
2022
Q4 | $9.3M | Sell |
129,260
-5,235
| -4% | -$395K | 0.31% | 77 |
|
|
2022
Q3 | $9.56M | Sell |
134,495
-884
| -0.7% | -$64.1K | 0.36% | 65 |
|
|
2022
Q2 | $10.4M | Sell |
135,379
-11,564
| -8% | -$881K | 0.37% | 62 |
|
|
2022
Q1 | $10.7M | Buy |
146,943
+3,602
| +3% | +$242K | 0.33% | 69 |
|
|
2021
Q4 | $8.94M | Buy |
143,341
+9,692
| +7% | +$569K | 0.27% | 86 |
|
|
2021
Q3 | $7.91M | Buy |
133,649
+4,193
| +3% | +$276K | 0.26% | 88 |
|
|
2021
Q2 | $8.65M | Sell |
129,456
-9,764
| -7% | -$637K | 0.29% | 81 |
|
|
2021
Q1 | $8.79M | Buy |
139,220
+7,009
| +5% | +$436K | 0.31% | 79 |
|
|
2020
Q4 | $8.2M | Sell |
132,211
-1,527
| -1% | -$93.9K | 0.31% | 75 |
|
|
2020
Q3 | $8.06M | Buy |
133,738
+9,095
| +7% | +$547K | 0.35% | 68 |
|
|
2020
Q2 | $7.33M | Buy |
124,643
+6,671
| +6% | +$399K | 0.35% | 69 |
|
|
2020
Q1 | $6.58M | Sell |
117,972
-739
| -0.6% | -$45.2K | 0.39% | 65 |
|
|
2019
Q4 | $7.62M | Buy |
118,711
+32,289
| +37% | +$1.85M | 0.36% | 71 |
|
|
2019
Q3 | $4.38M | Sell |
86,422
-439
| -0.5% | -$20.6K | 0.23% | 103 |
|
|
2019
Q2 | $3.94M | Sell |
86,861
-2,451
| -3% | -$114K | 0.22% | 103 |
|
|
2019
Q1 | $4.26M | Buy |
89,312
+5,121
| +6% | +$255K | 0.25% | 96 |
|
|
2018
Q4 | $4.38M | Buy |
84,191
+1,577
| +2% | +$84.7K | 0.28% | 87 |
|
|
2018
Q3 | $5.13M | Buy |
82,614
+2,185
| +3% | +$130K | 0.29% | 84 |
|
|
2018
Q2 | $4.45M | Sell |
80,429
-2,720
| -3% | -$147K | 0.27% | 90 |
|
|
2018
Q1 | $5.26M | Buy |
83,149
+738
| +0.9% | +$47.5K | 0.36% | 74 |
|
|
2017
Q4 | $5.05M | Sell |
82,411
-6,249
| -7% | -$391K | 0.34% | 76 |
|
|
2017
Q3 | $5.65M | Buy |
88,660
+7
| +0% | +$409 | 0.4% | 66 |
|
|
2017
Q2 | $4.94M | Sell |
88,653
-37,598
| -30% | -$2.05M | 0.37% | 69 |
|
|
2017
Q1 | $6.87M | Buy |
126,251
+3,543
| +3% | +$194K | 0.52% | 46 |
|
|
2016
Q4 | $7.17M | Sell |
122,708
-9,153
| -7% | -$500K | 0.57% | 43 |
|
|
2016
Q3 | $7.11M | Buy |
131,861
+2,500
| +2% | +$161K | 0.61% | 40 |
|
|
2016
Q2 | $9.51M | Buy |
129,361
+3,461
| +3% | +$245K | 0.84% | 25 |
|
|
2016
Q1 | $8.04M | Buy |
125,900
+39,279
| +45% | +$2.48M | 0.75% | 26 |
|
|
2015
Q4 | $5.96M | Buy |
86,621
+9,008
| +12% | +$595K | 0.55% | 48 |
|
|
2015
Q3 | $4.59M | Sell |
77,613
-647
| -0.8% | -$41K | 0.52% | 47 |
|
|
2015
Q2 | $5.21M | Sell |
78,260
-971
| -1% | -$64K | 0.55% | 45 |
|
|
2015
Q1 | $5.11M | Buy |
79,231
+4,741
| +6% | +$297K | 0.55% | 46 |
|
|
2014
Q4 | $4.4M | Buy |
74,490
+489
| +0.7% | +$27.6K | 0.47% | 54 |
|
|
2014
Q3 | $3.79M | Buy |
74,001
+1,577
| +2% | +$78.8K | 0.43% | 57 |
|
|
2014
Q2 | $3.51M | Buy |
72,424
+5,363
| +8% | +$264K | 0.4% | 67 |
|
|
2014
Q1 | $3.48M | Buy |
67,061
+69
| +0.1% | +$3.67K | 0.43% | 62 |
|
|
2013
Q4 | $3.56M | Sell |
66,992
-1,473
| -2% | -$75K | 0.47% | 58 |
|
|
2013
Q3 | $3.17M | Sell |
68,465
-4,526
| -6% | -$199K | 0.49% | 52 |
|
|
2013
Q2 | $3.26M | Buy |
+72,991
| New | +$3.17M | 0.53% | 42 |
|
Other funds holding BMY
Raymond James Trust's BMY Position: Q3 2024 in Review
Raymond James Trust increased its Bristol-Myers Squibb (BMY) stake by 5.3% in Q3 2024, buying an estimated $278K and bringing the position to 117,655 shares worth $6.09M. The position accounts for 0.13% of the portfolio, ranked #147.
Raymond James Trust first reported a position in BMY in Q2 2013 and has held it in 46 quarters since. The position peaked at $10.7M in Q1 2022. 2,258 funds tracked by Wall St. Rank hold BMY as of Q3 2024.
- Raymond James Trust held 117,655 shares of Bristol-Myers Squibb worth $6.09M as of Q3 2024.
- Raymond James Trust bought 5,932 Bristol-Myers Squibb shares in Q3 2024, an estimated $278K.
- Bristol-Myers Squibb made up 0.13% of Raymond James Trust's portfolio in Q3 2024, its #147 holding.
- Raymond James Trust first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 46 quarters since.
- Raymond James Trust's Bristol-Myers Squibb position peaked at $10.7M in Q1 2022.
- 2,258 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.
Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.